Table 2.
Association of the PHB_1630_C > T polymorphism with ovarian cancer risk in BRCA1 carriers
| All cases and controls | ||||
| Genotype | Cases (n = 127) n (%) | Controls (n = 127) n (%) | ORcrudeb (95% CI) | p |
| PHB_1630_C > T | ||||
| CC | 101 (80) | 102 (80) | 1.00 (reference) | |
| CT+TTa | 26 (20) | 25 (20) | 1.05 (0.54–2.04) | 1.00 |
| Cases and controls with risk factor information | ||||
| Genotype | Cases (n = 83) n (%) | Controls (n = 83) n (%) | ORadjc (95% CI) | p |
| PHB_1630_C > T | ||||
| CC | 64 (77) | 65 (78) | 1.00(reference) | |
| CT+TTa | 19 (23) | 18 (18) | 1.34 (0.59–3.11) | 0.49 |
a Due to the low proportion of <3% in patients and controls, CT and TT genotypes were combined.
b ORcrude: crude odds ratio.
c ORadj: odds ratio adjusted for age at menarche, age of first live birth, parity, breastfeeding, OC use, HRT, smoking and BMI.